the aid library

LIST OPTIONS

Filter

10877

HIV/AIDS surveillance in Europe 2017

A. Pharris; A. Stengaard World Health Organization (Europe); European Centre for Disease Prevention and Control (2017) C_WHO

2016 data The report was coordinated by Anastasia Pharris and Annemarie Stengaard. Report review and production support were provided by Andrew J. Amato-Gauci, Mike Catchpole, Denis Coulombier, Masoud Dara, Nedret Emiroglu, Rachel Katterl, Shahin Khasiyev, Valentina Lazdina, Teymur Noori, Marc... more

Download (207)

View PDF (222)

Special edition: HIV in MSM

I. Steffens; K. Hagmaier; K. Wilson; et al. Eurosurveillance (Europe’s journal on infectious disease epidemiology, prevention and control); European Centre for Disease Prevention and Control (2015) C2

Eurosurveillance Impact Factor 5.7 June 2015 www.eurosurveillance.org Featuring a series of articles on HIV and STI epidemiology, prevention and control among MSM in Europe

External Link

Diseño y validación de una encuesta solo sobre triquiasis-tracomatosa: Grupo Consultivo estratégico y técnico para enfermedades tropicales desatendidas, Grupo de trabajo sobre Monitoreo y evaluación

World Health Organization WHO (2017) C_WHO

La quincuagésima primera Asamblea de la Salud Mundial aprobó la resolución WHA51.11 en 1998, que busca la eliminación mundial del tracoma como problema de salud pública para el 2020 (1). La estrategia recomendada para lograr ese objetivo está encapsulada por las siglas "SAFE", que represent... more

Download (213)

View PDF (209)

L'Afrique face à la pandémie de la COVID-19

Bapoutou, B.; et al. Jésuites d'Afrique de l'Ouest (2020) CC

IBOGA Review No.1 Revue Scientifique du Jésuites d'Afrique de l'Ouest

Download (374)

View PDF (433)

Progress on drinking water, sanitation and hygiene in schools: 2000-2021 data update

World Health Organization WHO; UNICEF; et al. (2022) C_WHO

Special Focus on COVID-19 The report provides updated estimates for drinking water, sanitation and hygiene in schools including progress from 2015 to 2019. It highlights the rapid improvement needed to ensure students have access to handwashing facilities with soap and water during the COVID-19 pan... more

Download (779)

View PDF (846)

Action mondiale pour lutter contre les vecteurs 2017-2030 (Version 5.4)

Organisation mondiale de la Santé (OMS) (2017) C_WHO

Download (730)

View PDF (1257)

Sphere focal points strategy

The Sphere Project (2013)

The Sphere Project strategy for working with regional partners, country focal points and resource persons.

Download (202)

View PDF (183)

Bénin (Indice des composantes du programme maternel et néonatal)

MNPI (2003) C2

Chaque année dans le monde, plus de 500 000 femmes et filles meurent suite aux complications imputables à la grossesse et à l’accouchement. Plus de 99% de ces décès surviennent dans des pays comme le Bénin. Et pourtant les décès maternels ne racontent qu’une partie de la vérité. En e... more

Download (112)

View PDF (284)

The reality of managing asthma in sub-Saharan Africa – Priorities and strategies for improving care

Mortimer, K.; Masekela, R.; Ozoh, O.; et al. (2022) CC2

Asthma is the most common non-communicable disease in children and remains one of the most common throughout the life course. The great majority of the burden of this disease is seen in low-income and middle-income countries (LMICs), which have disproportionately high asthma-related mortality relati... more

Download (254)

View PDF (283)

Mental Health in the times of COVID-19 Pandemic

National Institute of Mental Health & Neurosciences, Bengaluru India; Dept. of Psychiatry (2020) CC

Guidance for General Medical and Specialised Mental Health Care Settings

Download (215)

View PDF (243)

South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection

World Health Organization (WHO), Regional Office for South-East Asia (2020) C_WHO

External Link

Acute Chagas Disease: New Global Challenges for an Old Neglected Disease

Andrade, D.; Gollob, K.; Dutra, W. PLoS Neglected Tropical diseases (2015) CC

Abstract: Chagas disease is caused by infection with the protozoan Trypanosoma cruzi, and although over 100 years have passed since the discovery of Chagas disease, it still presents an increasing problem for global public health. A plethora of information concerning the chronic phase of human Chaga... more

Download (1011)

View PDF (922)

Namibia: Nutrition guidelines for prevention and management of non-communicable diet related disease

Ministry of Health and Social Services (MOHSS) (2013) C1

External Link

Questions and Answers for Obstetrical Healthcare Providers: Pregnant Women and Zika Virus Infection

Centers for Disease Control and Prevention CDC (2022) C_CDC

English version

External Link

Mycetoma: epidemiology, treatment challenges, and progress

Taha, H.; Fahal, A.; Van de Sande, W. Dovepress open access to scientific and medical research (2015) CC

Mycetoma is a specific chronic, granulomatous, inflammatory disease. It usually involves the subcutaneous tissue, most probably after traumatic inoculation of the causative organism. It has a prolonged, progressive, and indolent course, and, if untreated, it ultimately leads to destruction of the de... more

Download (755)

View PDF (1563)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (335)

View PDF (446)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more